A New Era in Essential Tremor Care
Fasikl, a University of Minnesota spin-off company, has achieved a significant milestone: the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to its Felix™ NeuroAI™ Wristband, the first wearable device featuring adaptive AI therapy for adults with essential tremor.
Pioneered by MnDRIVE neuromodulation researcher, Dr. Zhi Yang—University of Minnesota Professor of Biomedical Engineering and co-founder and CEO of Fasikl—this innovation fuses bioelectronic medicine with artificial intelligence, redefining treatment paradigms for movement disorders
Why This Matters
Widespread Impact: Essential tremor is the most prevalent tremor disorder in the U.S., affecting approximately 7 million individuals—about seven times more than Parkinson’s disease.
Unmet Needs: Current treatments, ranging from medication (with inconsistent effects and side effects) to invasive options like deep brain stimulation, often fall short for many patients.
Smart & Noninvasive: Felix offers a watch-like, wearable solution—drug-free and surgery-free—that dynamically adapts stimulation via a cloud-based AI platform for continuous, personalized therapeutic relief.
Backed by Rigorous Science
The FDA clearance was granted on the strength of the TRANQUIL study—a randomized, double-blind, sham-controlled clinical trial. This study demonstrated:
Significant reductions in tremors
Meaningful improvements in daily functionality
Consistent efficacy across age, gender, tremor severity, and medication status
No serious device-related adverse events
These promising findings were presented under the “Late-Breaking Science” category at the 2025 American Academy of Neurology (AAN) Annual Meeting.
What’s Ahead
The Felix NeuroAI Wristband will be available by prescription through select U.S. healthcare providers starting late 2025, with broader nationwide rollout slated for 2026.
Expert Endorsements
Dr. Rajesh Pahwa, Professor of Neurology at the University of Kansas, sees the wristband as a critical leap in noninvasive, personalized treatment:
“Pharmaceutical treatments are helpful for less than 50% of the patients… this new AI wearable wristband backed by clinical evidence is an effective treatment option for patients with essential tremor.”
Dr. Zhi Yang, CEO of Fasikl and MnDRIVE Neuromodulation Researcher added:
“FDA clearance of Felix marks a defining moment… this breakthrough… marks the emergence of AI therapeutics in disease treatment. It offers a new option that is potentially more effective, safer, and more scalable.”
Bottom Line
The FDA’s clearance of the Felix NeuroAI Wristband marks a pivotal shift in how essential tremor may be managed—combining AI-driven personalization, noninvasive application, and clinical validation. As Fasikl prepares for its market debut, countless individuals living with essential tremor may soon gain access to a safer, more consistent, and effective therapy.
